Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ziopharm Oncology IN (ZIOP)

Ziopharm Oncology IN (ZIOP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 437,585
  • Shares Outstanding, K 215,559
  • Annual Sales, $ 0 K
  • Annual Income, $ -79,980 K
  • 60-Month Beta 2.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.03
Trade ZIOP with:

Options Overview Details

View History
  • Implied Volatility 107.02%
  • Historical Volatility 140.96%
  • IV Percentile 70%
  • IV Rank 22.70%
  • IV High 256.51% on 08/24/21
  • IV Low 63.13% on 05/25/21
  • Put/Call Vol Ratio 0.17
  • Today's Volume 1,756
  • Volume Avg (30-Day) 7,302
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 41,724
  • Open Int (30-Day) 39,113

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.15
  • Number of Estimates 3
  • High Estimate -0.11
  • Low Estimate -0.22
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.57 +35.03%
on 08/31/21
2.43 -12.76%
on 09/07/21
+0.36 (+20.45%)
since 08/27/21
3-Month
1.26 +68.25%
on 08/19/21
2.94 -27.89%
on 06/28/21
-0.74 (-25.87%)
since 06/25/21
52-Week
1.26 +68.25%
on 08/19/21
5.95 -64.37%
on 02/10/21
-0.33 (-13.47%)
since 09/25/20

Most Recent Stories

More News
Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway

? Over 50% reduction in personnel

ZIOP : 2.12 (+4.43%)
Is the Options Market Predicting a Spike ZIOPHARM (ZIOP) Stock?

Investors need to pay close attention to ZIOPHARM (ZIOP) stock based on the movements in the options market lately.

ZIOP : 2.12 (+4.43%)
Ziopharm Oncology to Participate in September Investor Conferences

Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual...

ZIOP : 2.12 (+4.43%)
Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions

Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles

ZIOP : 2.12 (+4.43%)
Ziopharm Oncology Provides Second Quarter 2021 Corporate Updates

Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company's manufacturing facility and presentation of favorable preclinical data

ZIOP : 2.12 (+4.43%)
Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial...

ZIOP : 2.12 (+4.43%)
Ziopharm Oncology to Participate in Upcoming Conferences

Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will...

ZIOP : 2.12 (+4.43%)
Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting

- Highlighted distinctive cellular therapy program, market opportunity and value proposition

ZIOP : 2.12 (+4.43%)
Ziopharm: Q1 Earnings Snapshot

BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Thursday reported a loss of $21.6 million in its first quarter.

ZIOP : 2.12 (+4.43%)
Ziopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Updates

- Annual shareholder meeting planned for May 19, 2021

ZIOP : 2.12 (+4.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and...

See More

Key Turning Points

3rd Resistance Point 2.35
2nd Resistance Point 2.26
1st Resistance Point 2.19
Last Price 2.12
1st Support Level 2.03
2nd Support Level 1.94
3rd Support Level 1.87

See More

52-Week High 5.95
Fibonacci 61.8% 4.16
Fibonacci 50% 3.61
Fibonacci 38.2% 3.05
Last Price 2.12
52-Week Low 1.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar